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Figure 1. Outcomes of Interaction of a Ligand with a P450
The interaction of a compound with a P450 (P450 3A4 structure is shown, pdb
code 1TQN) can be related to the chemical being a substrate, inhibitor, irre-
versible inhibitor, or stimulator—or combinations thereof. Also note that
many P450 ligands can interact via multiple binding modes, leading to multiple
products in the case of substrates (Guengerich, 2005).
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pre-incubation settings (Sil-
verman, 1995).
The results of Veith et al.
(2009) can be used to predict
inhibition by drug candidates,
but a number of other factors
are involved (Food and Drug
Administration, 2006) and
ultimately the true test for
inhibition is an in vivo human
experiment. The results can
also be used to predict if
compounds are substrates,
and the methods for following
these up are relatively
straightforward. Finally, the
information, if available, couldbe coupled with similar screens of other
libraries—perhaps even if run on different
platforms—to expand the results. The
database used in this analysis is available
in the online supplemental information.
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Cegelski et al. (2009) demonstrate the importance of amyloid production for biofilm formation and host colo-
nization using several mutant strains of pathogenic E. coli and small molecule inhibitors. This work reveals
a path forward for studying the role of bacterial amyloids in vivo and suggests the potential for small mole-
cules to target multiple biofilm formation pathways.The increased prevalence of antibiotic
resistant bacteria heralds a need for new
drugs and novel strategies for identifying
better drug targets. One such strategy
is to target microbial virulence factors,
which are important for causing pathology
but are not required for the microbe to
survive in vitro. This strategy avoids tar-
geting essential gene functions, which
may result in strong evolutionary selectionfor resistant strains. While this idea
remains theoretical, efforts have been
increased to develop new antibiotics
based on this principle. One virulence
process of particular interest to target is
biofilm formation because of the associ-
ated antibiotic insensitivity of bacteria
surviving within biofilms. Cegelski et al.
(2009) have recently generated tools to
allow researchers to address the relativeimportance of different bacterial attach-
ment strategies during biofilm formation
in vivo in a model for urinary tract infection.
Many pathogenic bacteria elaborate
virulence factors in order to cause dis-
ease. Examples of factors include secre-
tion systems to inject effector molecules
into host cells, secreted toxins that manip-
ulate host cell processes or outright kill
host cells, quorum-sensing systems that
Figure 1. Inhibition of In Vivo Biofilm Formation
(A) Structures of BibC10 and FN075.
(B) The stages of a biofilm life cycle involve attachment of free-swimming planktonic cells to a surface, microcolony formation, exopolymeric material production,
mature biofilm development, and the detachment of cells to start the process over as planktonic cells. FN075, used in the study, inhibits both UPEC pili and curli
production, preventing bacterial attachment and resulting in attenuation in an in vivo mouse bladder infection model.
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quently coordinate behavior, and biofilm
formation. Biofilms are complex, three-
dimensional bacterial communities
embedded in exopolymeric material that
is made up of polysaccharides, proteins,
and nucleic acids. Bacteria within these
communities are relatively insensitive to
antibiotics and host-immune responses,
allowing the development of persistent
infections and significant morbidity (Cos-
terton et al., 1999). Several of the mecha-
nisms resulting in antibiotic tolerance in
biofilms include slower bacterial growth,
alterations in antibiotic targets, expres-
sion of drug pumps and antibiotic-
degrading enzymes, and development of
persister cells, a population of cells that
neither grows nor dies when exposed toantibiotics. Biofilms complicate many clin-
ical infections, including endocarditis,
periodontal diseases, ear infections, pneu-
monia, and urinary tract infection (UTI).
They also form on implanted devices
such as catheters, artificial joints, stents,
and heart valves, which provide a surface
for bacteria to attach and biofilms to
develop within the host (Parsek and Singh,
2003). Thus, there is intense interest in
developing therapeutic agents to disrupt
and prevent biofilm development.
Biofilm formation is thought to occur
in response to environmental conditions
through a series of reversible stages
(Watnick and Kolter, 2000), depicted in
Figure 1. First, free-swimming planktonic
bacteria encounter a surface and form
loose attachments. Next, the bacteriaChemistry & Biology 16, December 24, 2009 ªmigrate across the surface to congre-
gate into a microcolony, where they lose
motility and often communicate through
quorum-sensing systems. Then, the col-
ony produces exopolymeric material,
resulting in a complex, three-dimensional
matrix in which the bacteria are antibi-
otic tolerant (O’Toole et al., 2000).
Finally, when the environmental condi-
tions change, some of the bacteria can
become motile, detach, and disperse to
more favorable locations.
Because the attachment of bacteria to
a surface is an early and critical step
in biofilm formation, it is an attractive target
for inhibitionbysmallmolecules.Uropatho-
genic E. coli (UPEC) assembles several
different structures on its cell surface to
enhance adherence to different types of2009 Elsevier Ltd All rights reserved 1217
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as curli, is composed of extracellular
amyloid fibers. These fibers are the major
proteinaceous component of a complex
extracellular matrix and play a role in bacte-
rial cell aggregation, host-cell adhesion,
adherence to surfaces of medical and
food-handling devices, and biofilm forma-
tion. Curli are long protein fibers that bind
to many host proteins, including fibro-
nectin, fibrinogin, and laminin, and do not
provide motility to the organism. In
contrast, another structure that plays
a role in bacterial surface adhesion is
type-1 pili, which are shorter rod-like struc-
tures that provide motility through their
contractile nature. Type-1 pili can bind
specifically to mannosylated host recep-
tors that are often found on epithelial cells
in the bladder. Despite their structural and
functional differences, curli and pili appear
to be able to play similar and/or comple-
mentary roles in promoting surface attach-
ment and subsequent biofilm formation.
Cegelski et al. (2009) have recently
reported efforts to develop small molecule
inhibitors of both curli and pili production
as an approach to inhibiting biofilm forma-
tion. Previously, they had reported a series
of inhibitorsof pili formation thatwere ratio-
nally designed based on the protein crystal
structure of the chaperone PapD (Pinkner
et al., 2006). One of these ‘‘pilicides,’’
BipC10, selectively disrupts the chap-
eron-usher interaction essential for pili
formation in UPEC (Pinkner et al., 2006).
Cegelski et al. (2009) expanded upon these
initial findings by synthesizing structural
analogs of BipC10, including FN075
(Figure 1A). Interestingly, slight chemical
modifications of BipC10 resulted in a gain
of ‘‘curlicide’’ activity in FN075 without
loss in pilicide function. The authors show
the curlicide activity of FN075 by demon-
strating reduced polymerization of the
main curli subunit (CsgA) and the loss of
curli structures typically visible on UPEC
by electron microscopy in the presence
of the compound. FN075 also inhibited
formation of pellicles, which are biofilms
formed at the air-liquid interface. None of
the compounds affected bacterial growth
in vitro, supporting the conclusion that curli
and pili are not essential in vitro.
Using fim and csgA mutants defective
in either pili or curli production, respec-
tively, the authors found that UPEC grown
in vitro in Luria broth required pili for biofilm
formation on polyvinyl chloride plastic, in1218 Chemistry & Biology 16, December 24,contrast to UPEC grown in YESCA broth
(yeast extract and casamino acids), which
required curli formation for biofilm forma-
tion. These results illustrate that different
mechanisms of attachment are likely
required for biofilm formation under
different environmental growth conditions.
Thisobservation highlightsone of the major
challenges of studying pathogenesis: the
ability to recreate the relevant in vivo envi-
ronmental conditions under in vitro condi-
tions, and the importance of understanding
the in vivo microenvironment. Unfortu-
nately, there is currently insufficient knowl-
edge regarding the microenvironments
important for most infections, making it
difficult to assign conditions for in vitro
studies. Combining this uncertainty with
the fact that UPEC can use either curli or
pili to promote surface attachment and
subsequent biofilm formation depending
on the conditions, it becomes important,
from a therapeutic standpoint, to inhibit
both mechanisms.
The authors show that FN075 is able to
inhibit biofilm formation under both
growth conditions. They then test FN075
in a mouse UTI model to demonstrate
that targeting biofilm production with
a chemical inhibitor could be an effective
route for reducing bacterial loads in the
bladder. The authors test E. coli grown
in pili-inducing conditions in the presence
of FN075 prior to challenge in a mouse
UTI bladder model. These pretreated
E. coli have decreased fitness similar to
the csgA mutant, as demonstrated by
modest reductions in both colony-
forming units and intracellular bacterial
communities. While this experiment
potentially addresses the role of pili inhibi-
tion in decreasing infection, it would have
been interesting to perform the converse
experiment, where E. coli are pretreated
in curli-inducing conditions with FN075
prior to challenge in a mouse UTI model
to test the importance of curli for in vivo
virulence. Further, the test ultimately will
be whether infected mice can be treated
directly with the inhibitor to protect from
infection, rather than pretreating the
bacteria, as performed here.
There remains work to be done to
confirm the role of curli in pathogenesis
separate from the role of pili. Cegelski
et al. (2009) provide mutant UPEC strains
as well as pilicide-only and curlicide-
pilicide compounds that will open up
research on the role of amyloid produc-2009 ª2009 Elsevier Ltd All rights reservedtion in UPEC attachment in UTI. Aside
from their potential as therapeutics, it is
important to recognize the value in having
these types of chemical tools that can be
used for probing the in vivo biology of bio-
film formation required for virulence under
different in vivo conditions. Researchers
can now combine pili or curli mutants
with pilicides or curlicide-pilicides in
different mouse models to investigate
the relevance of each component and
potentially use them to define the micro-
environments within the host.
This article represents a proof of prin-
ciple for the concept of using small mole-
cules that target multiple biofilm formation
pathways. It will be interesting to see if
these compounds limit the virulence of
other bacteria that similarly use curli and/
or pili for biofilm formation, such asSalmo-
nella, to determine how broad spectrum
such compounds or approaches may be.
Finally, while this work is a step toward
understanding the methods for targeting
the formation of biofilms, it may ultimately
be important, in order to have significant
clinical impact, to identify methods that
not only inhibit their formation, but are
also capable of disassembling pre-exist-
ing biofilms (Boles and Horswill, 2008;
Junker and Clardy, 2007). Efforts toward
this end will be needed in order to ulti-
mately obtain the therapeutics useful for
treating infections where biofilms play
a major role in the pathology.REFERENCES
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